Moolec Science SA MLEC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Moolec Science Successfully Completes 2026 GLASO Commercial Planting Campaign in the United States
-
Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period
-
Moolec Science Confirms Completion of First Phase of GLASO Industrialization Following Record 2025 Campaign; Advances 2026 Sowing and Expands Into Energy Applications
Trading Information
- Previous Close Price
- $7.48
- Day Range
- $7.00–7.79
- 52-Week Range
- $0.21–23.22
- Bid/Ask
- $6.50 / $7.34
- Shares Outstanding
- 725,565.00
- Market Cap
- $5.17M
- Volume/Avg
- 4,106 / 79,882
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 17.98%
Company Profile
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 72
- Website
- https://www.moolecscience.com
Valuation
|
Metric
|
MLEC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.70 |
Price/Sales | 0.01 |
Price/Cash Flow | — |
Price/Earnings
MLEC
Financial Strength
|
Metric
|
MLEC
|
|---|---|
Quick Ratio | 0.08 |
Current Ratio | 0.15 |
Interest Coverage | −2.96 |
Quick Ratio
MLEC
Profitability
|
Metric
|
MLEC
|
|---|---|
Return on Assets (Normalized) | −123.65% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −113.93% |
Return on Assets
MLEC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^<>k@R! | LOCK|YBdw? | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|YM<$x@$ | LOCK|wD%< | $70B | |||
| argenx SE ADR
ARGX
| LOCK|<mNRT> | LOCK|%Q | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|yCB?Tl | LOCK|!wRW@ | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<yt?ZF | LOCK|d>Z | $37B | |||
| Moderna Inc
MRNA
| LOCK|bh$zR## | LOCK|gk | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$<%#ksYf | LOCK|Fzy^ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|X@HdMbd | LOCK|bKj | $23B | |||
| Incyte Corp
INCY
| LOCK|%mty?h^ | LOCK|?&w | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$c$m@Y> | LOCK|&Q | $16B |
United States